BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33986743)

  • 1. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
    Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
    Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System.
    van der Sijde F; Mustafa DAM; Vietsch EE; Katsikis PD; van Eijck CHJ
    Pancreas; 2021 Aug; 50(7):933-941. PubMed ID: 34643608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 8. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy.
    Hane Y; Tsuchikawa T; Nakamura T; Hatanaka KC; Saito T; Tanaka K; Nakanishi Y; Asano T; Noji T; Okamura K; Shichinohe T; Yokota I; Hatanaka Y; Hirano S
    Pancreas; 2020 Oct; 49(9):1240-1245. PubMed ID: 32898010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
    Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
    Front Immunol; 2021; 12():728062. PubMed ID: 34691034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
    Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
    Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.